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Introduction
Valvular heart diseases remain a serious clinical condi-
tion, a major health problem and one of the main causes of 
morbidity and mortality worldwide. Even if the prevalence 
and incidence of valvulopathies increase with age, it repre-
sents an important problem for pediatric patients too (1% 
-2% of all live birth are affected by congenital heart diseases, 
the most common of which affects the heart valves) [1]. 
Etiology of heart valve diseases is various [2], inclu-
ding:
a. Congenital defects (bicuspid aortic valve, tetralogy 
of Fallot, congenital pulmonary valve insufficiency, pulmo-
nary artery hypoplasia).
b. Inflammatory/immunological disorders (rheumatic 
fever, syphilis, antiphospholipid syndrome, angiosarcoma 
of the aorta or pulmonary artery angiosarcoma).
c. Heritable disorders of connective tissue (Marfan syn-
drome).
d. Endocardial disorders with valvular involvement.
e. Diseases and disorders of other organs (such as, 
chronic renal failure).
f. Aging (valve calcification).
g. Post interventional valvular diseases.
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Abstract
Background: Heart valve disease is a clinically serious condition. The replacement of damaged valves practiced since the 1950’s is the ultimate treatment 
for end-stage heart failure caused by severe valve dysfunction. The choice of adequate prosthesis is challenging. Unfortunately, the treatment options 
available today do not satisfy completely physicians and scientists’ needs. Mechanical valves require long-term anticoagulation therapy because of poor 
hemocompatibility. Biological substitutes have better hemodynamics, but need replacement in ~ 10 years due to calcification and degeneration. In order 
to overcome the shortcomings of current treatment options many researches are motivated to fabricate a functional, living heart valve replacement by 
tissue engineering.
Conclusions: Tissue engineering is a promising approach that may lead novel constructs that will satisfy the need and overcome the limitations of current 
valve prosthetics. Scaffolds, fabricated from synthetic or biological materials, do not require donor tissue, but have struggled to recreate the macro- and 
micro valve anatomy and mechanical properties of native valve. Decellularized cardiovascular grafts have the opportunity to improve patients care by 
reducing the risk of sensitization to donor antigens, calcify and stenosis and providing with a good graft that will grow (especially important in children). 
In this way the emotional and financial drain on the patient and family of enduring multiple surgeries may be significantly minimized. The choice of 
decellularization method can be rational if mechanism of action is contemplated and clearly understood. 
Key words: tissue engineering of heart valve, decellularized scaffolds, hybrid starter matrices.
For better understanding of valve condition and pro-
duced pathophysiological disturbances it is necessary to 
know the role of each heart valve.
The heart consists of four chambers: two atria and 
two ventricles, and four flap-like membranous structures, 
namely valves. Valves determine the direction of blood flow 
from the atria to the ventricles and from the ventricles to the 
great vessels. 
The valves located between the atria and ventricles, or 
atrioventricular valves, are:
· Tricuspid valve, between the right atrium and right 
ventricle.
· Mitral valve, between the left atrium and the left ven-
tricle.
The valves located between the ventricles and great ar-
teries, or the semilunar valves, are:
· Pulmonary valve, between the right ventricle and pul-
monary artery.
· Aortic valve, between the left ventricle and aorta.
As it is known, the cardiac cycle consists of two phases: 
diastole phase and systole phase. During the diastole phase, 
the atrioventricular valves are opened and semilunar valves 
are closed, and during the systole phase, the atrioventricular 
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valves are closed and semilunar valves are opened, passive 
openings and closings being determined by a transvalvular 
pressure gradient. When the valve is damaged or diseased, it 
does not open or close properly and the blood flow becomes 
disrupted [3]. 
 Valvular heart diseases can be broadly characterized by 
the following pathological disorders:
· Stenosis: the valve opening becomes restricted and the 
blood flow out is prevented. In order to move blood, 
the heart needs to contract with increased force; 
· Regurgitation: the valve does not fully close, caus-
ing the blood flowing back instead of forward flow 
through the valve;
· And heart valves can have both malfunctions at the 
same time [4, 5].
The contemporary medicine offers a few strategies for 
the treatment of heart valve diseases: special medications 
that help to control the symptoms and to avoid further valve 
damage (diuretics, anti-arrythmic medications, vasodila-
tors, etc.), valve repair, and valve replacement.
Since the first mitral valve repair in 1923 and the first 
successful prosthetic valve replacement in 1960 described 
by Starr and Edwards, surgery for valvular diseases has ad-
vanced significantly [6]. 
Due to better long-term results of valve repair and lower 
morbidity and mortality this procedure is used in prefer-
ence when possible [7]. However, when heart valve repair is 
not possible, open-heart surgery with removing of damaged 
valve and implantation of an artificial one in its place is rec-
ommended. During the last decades more than 80 models 
of prostheses have been developed, however, none of them 
corresponds completely to the criteria of an “ideal” product, 




Ø Availability in a range of sizes,
Ø Excellent handling characteristics,
Ø Long-term valve function,
Ø Low-to-moderate price,
Ø Low infections potential,
Ø Potential for growth (in particular in pediatric pa-
tients).
Mechanical and biological valve substitutes used cur-
rently have struggled to recreate the macro- and micro- 
valve anatomy and mechanical properties of native valve 
[11]. As a result, their long-term performance is associated 
with major limitations. Thus, none of them may be consid-
ered “ideal” solution. 
Mechanical valve substitutes: general characteristic
Three types of mechanical valvular prosthesis are avail-
able now: ball valves, disc valves, or monoleaflet valves, and 
bileaflet valves. 
Even if mechanical valves remain the most structurally 
durable replacements, they have poor hemocompatibility 
because of their non-physiological surfaces and flow ab-
normalities. As a result, life-long anticoagulation therapy is 
necessary for prevention of thromboembolic complications. 
At the same time, anticoagulation therapy can cause serious 
spontaneous bleeding and embolism [12]. In addition, me-
chanical valve substitutes are noisy and susceptible to infec-
tion [13, 14].
Biological valve substitutes: general characteristic
By application in practice of biological heart valve re-
placements the hazards of anticoagulation treatment were 
avoided. 
Different types of bioprosthetic valves are described, 
such as autografts, xenografts (for example, porcine aortic 
valves or bovine pericardial valves) and homografts, or al-
lografts (valves taken from human donors) [8, 15]. 
 In 1967 Donald Ross [16] described a new procedure 
for the treatment of aortic valvular disorders. It involves 
replacement of patient diseased aortic valve with his own 
pulmonary valve and then installation of a mechanical or 
bioprosthetic valve in the hemodynamically weaker pulmo-
nary position. The procedure is associated with a significant 
surgical risk and risk of postoperative complications, trans-
forming the patient with one pathological valve into a pa-
tient with two diseased valves.  
Even if cryopreserved, donor valves are closest to the 
natural valve, have low thrombogenicity, superior hemody-
namic performance and resistance to infection. Their main 
disadvantages are limited availability and failure to regener-
ate and grow in vivo. Moreover, the recipient can become 
sensibilized to the donor Major Histocompatibility Complex 
(MHC) antigens, which are present in endothelial cells lin-
king the luminal surface (MHC I) and smooth muscle cells 
in the media of the arterial wall (MHC II) [17]. Also, when 
compared to mechanical valves, the structural degeneration 
of bioprosthetics due to inflammatory/immune response 
and calcification occurs earlier (in about 10-20 years).
None of currently available biological substitutes shows 
any potential to grow, regenerate and develop in vivo. All 
these characteristics are important especially in the treat-
ment of pediatric patients [18]. 
Even the progress in the field of development of new 
types of valve replacements is undoubted, tissue engineer-
ing is the unique approach that may propose a promising 
strategy to overcome the limitations mentioned above and 
to provide the surgeons with alternative suitable substitutes, 
which are able to grow and remodel as the age of the pa-
tients advances [19, 20].
Material and methods
Articles containing the keywords “Valvular diseases”, 
“Heart valve replacement”, “Tissue Engineering of Heart 
Valves”, “Polymeric starter matrices”, “Decellularization”, 
“Decellularized scaffolds”, “Biological/Polymeric starter 
matricies” were selected from PubMed and SpringerLink 
databases. 
The following filters were used: articles published since 
January 2008 in English. After a preliminary analysis the 
bibliography of the identified articles has been studied also 
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in order to find other relevant articles on this topic. Sub-
sequently, information was systematized highlighting the 
main aspects of contemporary vision on advantages and 
disadvantages of existing heart valve replacements, scaf-
folds used in fabrication of a tissue engineered heart valve, 
improving the procedures of scaffolds development, main 
characteristics of new valvular prostheses. 
Discussion
Being motivated by the lack of adequate replacements 
pediatric surgeons were the first who introduced the con-
cept of tissue engineering of heart valve [12] and, perhaps, 
Grim et al were the first who presented an example of a 
tissue-engineered heart valve at the University of Vienna in 
1990’s. They demonstrated the possibility of including and 
growing of endothelium on glutaraldehyde-fixed bovine 
pericardium [21]. Between February 1986 and February 
1992, 144 patients received 149 bovine pericardial valve bio-
prostheses. Even short-term results were satisfactory, long-
term results were as follows – 10 patients required reopera-
tion because of valvular dysfunction (valvular stenosis – 7, 
valvular regurgitation – 2, paravalvular leakage - 1), defect 
bioprosthesis being removed 34 to 81 months after implan-
tation [22].
The advancement in the field of heart valve tissue en-
gineering since the first published study till today is un-
doubted. Future development of TEHV needs elaboration 
of appropriate starter matrices that are able to support cell 
growth and cell-to-cell interaction with tissue formation. 
Apart from standard requirements for general tissue-engi-
neered scaffold, like biodegradability, biocompatibility and 
non-immunogenicity, scaffolds used for tissue engineered 
heart valve (TEHV) should correspond to several other im-
portant criteria [4, 23-26]:
Ø Non-thrombogenicity.
Ø Mechanically resistance.
Ø Growth with patient.
Ø Anatomically-shaped.
Ø Non-obstruction.
Ø Ability to close promptly and completely.
According to these criteria, three main types of starter 
vehicles are applied in TEHV:
· Polymeric (synthetic) bioresorbable starter matrices 
(such as polyglatin, polyglicolic acid, polylactic acid 
etc.),
· Decellularized allogeneic starter matrices, 
· Biological / Polymeric hybrid starter matrices [4].
A. Characteristics of Polymeric Scaffold
The concept of use of polymeric starter matrices in tissue 
engineering is simple – the cells of a particular phenotype 
seeded on a porous material are expected to generate the 
tissue growth and organ formation as the scaffold degener-
ates (important, the degeneration rate of the scaffold should 
be controllable and proportional to the rate of tissue forma-
tion). Except being biocompatible and biodegradable, the 
vehicles used should match the mechanical properties of 
the native tissue, exhibit a cell-favourable surface chemistry 
and to be at least 90% porous (interconnected pore network 
is essential for cell growth, nutrient supply and removal of 
metabolic waste products) [27].
The first models of synthetic biodegradable scaffolds 
were constructed from aliphatic polyester like polyglatic 
(in 1995), polyglicolic acid (PGA, in 1996), polylactic acid 
(PLA, in 1998) and copolymer of PGA and PLA (PGLA, in 
1997) [25, 26, 28, 29]. Because these materials demonstrated 
to be too stiff, new more compliant scaffolds, like polyhy-
droxyalkanoate (PHAs, in 2000) and poly-4-hydroxybutyr-
ate (P4HB, in 2000) have been investigated [30] to create 
trileaflet heart-valve conduits. Combination of aliphatic 
polyesters and PHAs, as alternative composite polymers, 
has demonstrated promising results in TEHV [31]. 
As conclusion, the use of polymeric starter matricies 
has been already broadly demonstrated for cardiovascu-
lar tissue-engineering [12] with good results at short-term 
follow-up. Unfortunately, the mid- to long-term results are 
not clear yet.
B. Characteristics of decellularized starter matrices
It has been supposed that by decellularization of cryo-
preserved cardiovascular grafts and removal of donor cells 
and cell membrane associated MHC I/MHC II proteins the 
immunogenic potential may be reduced. The main challenge 
remains elaboration of an appropriate processing method.
According to the definition, decellularization is the pro-
cess of removing cellular (including nuclear) material from 
the extracellular matrix (ECM) with its’ preservation. Un-
altered extracellular matrix and proteins play an important 
role in promoting tissue regeneration and repair and serve 
as a native scaffold for cell migration growth and differentia-
tion [32, 33].
The first clinical implantation in pediatric patients of 
decellularized homografts engineered with autologous en-
dothelial progenitor cells for pulmonary valve replacement 
was performed in 2002 (since 2005 only non-seeded decel-
lularized allografts have been implanted). The first clinical 
application in humans of decellularized aortic homografts 
for aortic valve replacement was performed in February 
2008 in Chisinau, the Republic of Moldova [15].
There are different methods used for tissue decellulariza-
tion, such as [34]:
a. Chemical agents:
· Acids and bases.
· Hypotonic and hypertonic solutions.
· Detergents: ionic – sodium dodecyl sulphate (SDS), 
sodium deoxycholate (SDC), N-Lauroylsarconsinate 
(NLS); non-ionic – Triton X-100, Tween-20; and – 
zwitterionic detergents.
· Other solvents – alcohols, acetone, tributyl phosphate 
(TBP).
Complete removal of residual chemicals from ECM af-
ter decellularization is obligatory, because even low residual 
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b. Biological agents [34]:
· Enzymes: nucleases – DNase and RNase; trypsin; col-
lagenase; lipase; dispase, etc. 
· Non-enzymatic agents: chelating agents – ethylenedi-
aminetetraacetic acid (EDTA), ethyleneglycoltetraace-
tic acid (EGTA).
c. Physical and miscellaneous agents [36-38]: 
· Temperature (freeze-thaw processing).
· Force and pressure: mechanical abrasion.
· Non-thermal irreversible electroporation.
Because of a variety of techniques, in the context of heart 
valve decellularization the following criteria were elaborat-
ed [17, 31, 32]:
Ø It should be stringent enough to ensure completely 
cellular material removal (DNA, mitochondria, mem-
brane lipids, cytosolic proteins) in order to avoid any 
adverse cellular immune response post-implantation.
Ø It should be gentle enough to preserve the biomechan-
ical strength and structural properties of the remain-
ing ECM, because the conduits and leaflets are under 
extreme environmental demands.
Ø It should preserve potential for recellularization.
Ø It should reduce of immunogenicity and thrombo-
genicity.
Broadly speaking, the choice of the method of process-
ing is of key importance in decellularization strategy.
The most often employed decellularization combina-
tions for cardiovascular tissue
It’s very important to understand the effects of the de-
cellularization technology on the properties of donor heart 
valve.
a. Biological agents [32, 39, 40]
· Nucleases (DNase/RNase) cleave nucleic and se-
quences into shorter segments, expediting their removal 
from the ECM.
· Trypsin (a serine protease) cleaves proteins hydrolyti-
cally and is used to digest cellular proteins in the decellu-
larization process. Because the structural proteins of ECM 
have limited resistance to trypsin cleavage, visible histologi-
cal damage to the ECM is often determined. As conclusion, 
even it is known that tyrosine cleaves proteins at the argi-
nine or the lysine amino acid residue on the carboxyl side, 
except when followed by proline; it is capable of degrading 
the extracellular matrix and cannot be considered a “per-
fect” strategy for decellularization of cardiac tissue.
· Trypsin+ EDTA, most often employed enzyme-based 
combination. Intracellular proteases released as the cells are 
being trypsinized are inactivated by EDTA.  In this way deg-
radation of extracellular matrix by proteases can be avoided, 
but, unfortunately, all the proteolytic activity of the intracel-
lular proteases cannot be inhibited by it.
Thus, biomechanical integrity of ECM could be adverse-
ly affected due to aggressive effect of biological agents.
b. Chemical agents
Detergents have a hydrophilic head and hydrophobic 
tail, and by reducing the surface tension of the local envi-
ronment they can penetrate the extracellular matrix and cell 
membranes [41]. They are classified into three main catego-
ries based on the property of the hydrophilic head group: 
non-ionic, ionic, and zwitterionic.
Detergents are very effective agents because they are able 
to solubilize cell membrane, lyse cells, and dissociate DNA.
Characteristics of ionic detergents
Ionic detergents contain a head group with a net charge 
that can be either negative (anionic) or positive (cationic). 
Ionic detergents can disrupt protein-protein interactions 
along with lipid-lipid and lipid-protein interactions, and 
they may denaturate proteins [42].
Anionic detergents (SDS, SDC) are stronger solubilizing 
agents than non-ionic detergents and are often used in valve 
decellularization for cells and DNA removing from ECM 
[32].
· SDS (Sodium-dodecyl-sulphate) is a good candidate 
detergent due to its known ability to denaturate proteins 
[42], but also SDS has the potential to reduce the biome-
chanical strength of obtained cell-free scaffold, predispos-
ing the allograft to anevrysm formation once in vivo, and 
to increase the immunogenic potential of the allograft due 
to denaturation of the extracellular matrix proteins [8]. In 
addition, complete SDS removal from the tissue is difficult 
and residual detergents can adversely affect cell adhesion 
and repopulation [35].
So, SDS seems to be effective for removing cell residues 
from tissue compared to other detergents, but it is also dis-
ruptive to ECM [43].
· SDC (Sodium Deoxycholate) is an ionic detergent 
(even it tends to act more like a non-ionic detergent, be-
cause of its polar properties it is classified as ionic one) that 
is useful for disrupting and dissociating many types of pro-
tein interactions [44].
· NLS (N-Lauroyl Sarconsinate) is an effective solubiliz-
er that permits a complete decellularization, additionally it 
possesses bactericidal properties [45]. In conjunction with a 
recombinant endonuclease it has been successfully utilized 
to decellularize pulmonary artery patch grafts [46, 47].
Characteristics of non-ionic detergents
Non-ionic detergents contain unchanged hydrophilic 
head groups and are suited for breaking lipid-lipid and 
lipid-protein interactions [42]. Even if Triton X-100 has 
proven effective at cell and DNA removal from thicker tis-
sues where enzymatic and osmotic methods are insufficient 
and appears to be more effective for tissue delipidation than 
ionic detergents [35, 48], it has demonstrated to lack suffi-
cient strength to decellularize cardiovascular tissue in some 
hands.
Characteristics of zwitterionic detergents
Zwitteronic detergents offer combined properties of 
ionic and non-ionic detergents. They do not possess a net 
charge like non-ionic detergents, but are able to break pro-
tein-protein interactions like ionic detergents [42]. For ex-
ample, CHAPS (3-(cholamidopropyl)dimethylammonio)-
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1-propansulfonate) is effective for decellularization of 
thinner tissues and is less effective for cell removal from 
thicker tissues [49].
To summarize, there are many different detergents that 
can be used in decellularization protocols, but it is critical to 
understand how different detergents with distinct chemical 
properties effect ECM scaffolds in the process of decellular-
ization [42].
c. Osmotic gradient, or osmotic shock, can be used to 
lyse cells, but it is not efficient at removing the hydrophobic 
cell membranes and remnants. Thus, it cannot be recom-
mended as the sole decellularization technique [50, 51], but 
if used in combination with detergents or enzymatic-based 
methods as an initial step, the required enzyme concentra-
tions and/or exposure time may be reduced [52, 53].
The methodical evaluation of the effect of different 
agents on the ECM scaffold can be performed by applying 
the following criteria (safety and effectiveness assessments) 
[4, 17]:
1. DNA content: < 50 ng ds DNA/mg ECM (dry weight) 
or < 200 bp DNA fragment lengths.
2. Histological and immunohistochemical assessments: 
2.1 Hematoxylin and Eosin (H&E) and 4,6-diamidino-
2-phenylindole (DAPI) assess for cellularity and inflamma-
tion (lack of visual nuclear material).
2.2 Movat’s Pentachrome assesses for extracellular ma-
trix structure.
2.3 Alizarin Reds assesses for the presence of calcifica-
tion.
2.4 Factor VIII assesses for the presence of endothelia 
cells.
2.5 Alpha smooth muscle actin assesses for myofibro-
blasts and smooth muscle cells.
2.6 TUNEL assesses for apoptotic cells and Hsp 27 as-
sesses for this chaperonin protein specifically expressed 
during the manufacture of collagen Types I and III.
3. Residual assessment: 
3.1 Enzyme Residuals may be assessed by ELISA, mass 
spectroscopy or zymography.
3.2 Detergent Residuals can be assessed by radiolabeling 
the detergent and conducting a time course experiment or 
performing a colorimetric assay.
4. Biomechanical assessments:
4.1 Uniaxial tensile.
4.2 Ball burst testing (assesses the biaxial strength of the 
conduit).
4.3 Fluid mediated burst.
4.4 Hydrodynamic assessment
4.5 Durability testing.
4.6 In vivo, durability and functional assessments usually 
performed in the female juvenile sheep model (according to 
ANSI/ISO/AAMI 5840 “Cardiovascular Valve Prostheses”).
To summarize, decellularization of the tissue to produce 
extracellular matrix (ECM) scaffold is a complex process 
that is not standardized even for a specific anatomic source 
tissue, furthermore it is highly desirable to preserve the 
complex composition and three-dimensional ultrastruc-
ture of the ECM. But it is recognized that all methods of 
tissue decellularization result in some degree of disruption 
of the architecture with potential loss of surface structure 
and composition, that may subsequently impact the host 
response (such as chronic inflammation, fibrotic encapsula-
tion, and scar tissue formation or a constructive remodeling 
response with the formation of site-specific functional tis-
sue) [34, 42, 54].
Numerous protocols with applying different agents for 
decelularization are reported. However, no references exist 
on how each one may affect the properties of the final ECM 
scaffold. 
C. Characteristics of biological/polymeric starter ma-
tricies
The engineered construct with single material and single 
technique can hardly mimic the whole structure, proper-
ties, and function of native valve tissue [5]. Biological/
polymeric composite materials are complex structures and 
have recently been introduced as a further strategy in tis-
sue-engineering. These hybrids may be used for production 
of heart valves, e. g. fabricated from decellularized porcine 
aortic valve and enhanced with bioresorbable polymer. As-
sessments of a novel hybrid heart valve (tensile tests, suture 
retention strength, pulse duplicator system used for func-
tional testing of the valve under physiological systemic load 
conditions) demonstrated its feasibility for an application in 
tissue engineering [12, 55].
Conclusions
Fabricating of a living valve that can grow and function-
ally integrate to patients’ cardiovascular system is the ulti-
mate goal. Heart valve tissue-engineering is a field already 
almost 20 years old and has advanced considerably since 
the first published study that galvanized the research. Tis-
sue engineering is a promising approach that may lead novel 
constructs that will satisfy the need and overcome the limi-
tations of current valve prosthetics. 
Some more common and traditional techniques have 
been improved, including using biopolymers and decellu-
larization. Scaffolds, fabricated from synthetic or biological 
materials, do not require donor tissue, but have struggled to 
recreate the macro- and micro valve anatomy and mechani-
cal properties of native valve.
Decellularized cardiovascular grafts have the opportu-
nity to improve patients care by reducing the risk of sen-
sitization to donor antigens, calcification and stenosis and 
providing with a good graft that will grow (especially im-
portant in children). In this way the emotional and finan-
cial drain on the patient enduring multiple surgeries may be 
significantly minimized. Decellularization process typically 
involves exposure to different agents (chemical, biological, 
physical ones) that unavoidably cause disruption of the as-
sociated ECM. Although some of decellularized valve tech-
nology showed promising results, the critical weakness of 
obtained decellularized TEHV is a somewhat unpredictable 
rapid graft failure because of immune response and incom-
53
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plete recellularization. As conclusion, the choice of decellu-
larization method can be rational if mechanism of action is 
contemplated and clearly understood. In addressing to chal-
lenges associated with the TEHV, researches must achieve 
the following goals:
· Improvement of decellularization technique.
· Preservation of valve biomechanical properties (equal 
with valve functional safety).
· Achieving of the entire valve recellularization in vivo. 
To summarize, many challenges have been encountered 
in the pursuit of a TEHV and, probably, it may take another 
20 years before many complex challenges are finally solved.
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